Tigemonam is a monobactam, a novel orally administered monobactam that protects against gram-negative aerobic bacterial pathogens and is at least as active against clinical isolates of Enterobacteriaceae as amitraz or carmonan (MIC90: 0.06-16 mg/l).

6'-Sialyllactose Sodium Salt (6'-N-Acetylneuraminyl-D-lactose sodium salt), an oligosaccharide present in breast milk, is protective against LPS-induced ALI and attenuates LPS-induced lung injury by inhibiting the STAT1 and NF-κB signaling pathways. Diquat dibromide

Gentisic acid is a dihydroxybenzoic acid.